title: Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
abstract: Inhibitor 2 of protein phosphatase 2A (I2PP2A), a biological inhibitor of the cellular serine/threonine protein phosphatase PP2A, is associated with numerous cellular processes that often lead to the formation and progression of cancer. In this study we hypothesized that targeting the inhibition of I2PP2A's multiple functions in prostate cancer cells might prevent cancer progression. We have investigated the effect of the small chain C6-ceramide, known to be a bioactive tumor suppressor lipid, on I2PP2A function, thereby affecting c-Myc signaling and histone acetylation in cells. Our data indicated that C6-ceramide treatment of prostate cancer cells induces cell death in PC-3, DU145, and LNCaP cells, but not normal prostate epithelial cells. C6-ceramide was able to disrupt the association between PP2A and I2PP2A. C6-ceramide inhibits I2PP2A's upregulation of c-Myc and downregulation of histone acetylation in prostate cancer cells. Our data indicated that targeting cancer related signaling pathways through I2PP2A using ceramide as an anti-I2PP2A agent could have beneficial effects as a therapeutic approach to prevent prostate cancer.
authors.affiliation: Higuchi Biosciences Center; The University of Kansas; Lawrence, KS USA.
authors.forename: Archana
authors.initials: A
authors.lastname: Mukhopadhyay
authors.forename: Kayann
authors.initials: K
authors.lastname: Tabanor
authors.forename: Rathnam
authors.initials: R
authors.lastname: Chaguturu
authors.forename: Jane V
authors.initials: JV
authors.lastname: Aldrich
mesh_terms: D000107:Acetylation; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival; D002518:Ceramides / Q000378:metabolism / Q000494:pharmacology*; D004268:DNA-Binding Proteins; D004847:Epithelial Cells / Q000378:metabolism; D055785:Gene Knockdown Techniques; D056488:Histone Chaperones / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006657:Histones / Q000378:metabolism; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D010749:Phosphoprotein Phosphatases / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000071636:Protein Phosphatase 2C; D011499:Protein Processing, Post-Translational; D034741:RNA, Small Interfering / Q000235:genetics; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D002518:Ceramides; D004268:DNA-Binding Proteins; D056488:Histone Chaperones; D006657:Histones; D034741:RNA, Small Interfering; C513473:SET protein, human; D014157:Transcription Factors; C101954:N-caproylsphingosine; D010749:Phosphoprotein Phosphatases; D000071636:Protein Phosphatase 2C
keywords: c-Myc; cell signaling; ceramide; histone acetyl transferase; inhibitor 2 of protein phosphatase 2A; protein phosphatase 2A; tumor suppressor lipid
references.citation: J Biol Chem. 2003 Jan 31;278(5):2837-44
references.pmid: 12444089
references.citation: FEBS Lett. 2006 Oct 9;580(23):5467-76
references.pmid: 16970943
references.citation: Prostate Cancer. 2012;2012:327253
references.pmid: 22530130
references.citation: Radiat Oncol. 2010 Nov 16;5:108
references.pmid: 21080918
references.citation: Oncogene. 2011 Jun 2;30(22):2504-13
references.pmid: 21297667
references.citation: Trends Mol Med. 2008 Apr;14(4):152-60
references.pmid: 18329957
references.citation: Mol Cell Biol. 2005 Jan;25(2):797-807
references.pmid: 15632079
references.citation: J Biol Chem. 2003 Jan 10;278(2):1158-64
references.pmid: 12407107
references.citation: J Am Soc Nephrol. 1998 Oct;9(10):1873-80
references.pmid: 9773788
references.citation: Nature. 2005 Jun 30;435(7046):1262-6
references.pmid: 15988529
references.citation: Int J Cancer. 2006 Nov 1;119(9):2119-26
references.pmid: 16823850
references.citation: Cell. 2001 Jan 12;104(1):119-30
references.pmid: 11163245
references.citation: Mol Cancer Ther. 2006 Feb;5(2):200-8
references.pmid: 16505092
references.citation: J Cell Mol Med. 2010 Jun;14(6B):1668-82
references.pmid: 19583812
references.citation: Nat Rev Cancer. 2013 Jan;13(1):51-65
references.pmid: 23235911
references.citation: Oncogene. 2006 Jul 6;25(29):4033-42
references.pmid: 16474839
references.citation: Expert Opin Pharmacother. 2011 Apr;12(6):977-82
references.pmid: 21406025
references.citation: FASEB J. 2009 Mar;23(3):751-63
references.pmid: 19028839
references.citation: Biochemistry. 1995 Feb 14;34(6):1988-96
references.pmid: 7531497
references.citation: Glia. 2002 Aug;39(2):105-13
references.pmid: 12112362
references.citation: J Biol Chem. 1994 Jan 21;269(3):2258-62
references.pmid: 8294483
references.citation: Cancer Metastasis Rev. 2008 Jun;27(2):147-58
references.pmid: 18246411
references.citation: Prostate. 2003 Sep 15;57(1):66-79
references.pmid: 12886525
references.citation: EMBO J. 2007 Jan 24;26(2):336-45
references.pmid: 17245428
references.citation: World J Urol. 1996;14 Suppl 1:S21-5
references.pmid: 8738406
references.citation: Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
references.pmid: 18216770
references.citation: Int J Cancer. 2003 May 20;105(1):1-6
references.pmid: 12672022
references.citation: Cell Death Differ. 2003 Feb;10(2):240-8
references.pmid: 12700652
references.citation: Biochemistry (Mosc). 1998 Sep;63(9):1057-60
references.pmid: 9795275
references.citation: Nat Rev Cancer. 2004 Aug;4(8):604-16
references.pmid: 15286740
references.citation: Cancer Res. 2005 Jun 1;65(11):4578-86
references.pmid: 15930275
references.citation: Clin Cancer Res. 2013 Mar 15;19(6):1335-9
references.pmid: 23300275
references.citation: Ther Adv Med Oncol. 2013 Jan;5(1):25-40
references.pmid: 23323145
references.citation: Mol Endocrinol. 2000 Jun;14(6):875-88
references.pmid: 10847589
references.citation: Cancer Metastasis Rev. 2008 Jun;27(2):159-68
references.pmid: 18213449
references.citation: Cancer Cell. 2005 Nov;8(5):355-68
references.pmid: 16286244
references.citation: Mol Cancer Ther. 2012 Nov;11(11):2352-61
references.pmid: 22962326
references.citation: Proc Natl Acad Sci U S A. 1995 May 9;92(10):4279-83
references.pmid: 7753797
references.citation: Clin Cancer Res. 2005 May 1;11(9):3465-74
references.pmid: 15867249
references.citation: Cancer Res. 2006 Jan 15;66(2):820-7
references.pmid: 16424014
references.citation: Methods. 2006 Jun;39(2):82-91
references.pmid: 16828308
references.citation: PLoS One. 2012;7(7):e40594
references.pmid: 22808202
references.citation: Oncogene. 2012 Oct 25;31(43):4588-98
references.pmid: 22179832
references.citation: Cell. 2003 Mar 7;112(5):659-72
references.pmid: 12628186
references.citation: Mol Cell Biol. 2006 Apr;26(7):2832-44
references.pmid: 16537924
references.citation: Cell Death Dis. 2011 Jan 27;2:e117
references.pmid: 21368888
references.citation: Biochim Biophys Acta. 2008 Oct;1783(10):1718-27
references.pmid: 18598724
references.citation: Cancer Cell. 2002 Aug;2(2):113-6
references.pmid: 12204531
references.citation: J Biol Chem. 1996 May 10;271(19):11059-62
references.pmid: 8626647
references.citation: Nat Rev Cancer. 2001 Oct;1(1):34-45
references.pmid: 11900250
references.citation: Cancer Res. 2004 Jan 1;64(1):55-63
references.pmid: 14729608
references.citation: Cancer Cell. 2006 Apr;9(4):287-300
references.pmid: 16616334
references.citation: Curr Cancer Drug Targets. 2009 Mar;9(2):237-49
references.pmid: 19275762